Frontlight ResearchEarly access
CompletedPhase 1
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
Key facts
- Who runs it
- Orphalan
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 26 people enrolled
- Started
- 16 Jan 2024
- Ended
- 16 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 900mg TETA 4HCl Once Daily Formulation
- 900mg TETA 4HCl Cuprior®
- Record updated
- 26 August 2026
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age: 18 to 40 years
- Body weight: ≥ 50 kg
- BMI: 18.0 to 25.0 kg/m2
- Health: Generally healthy, with no clinically significant illnesses or surgeries in the past 12 weeks
- Willingness to comply with trial procedures and restrictions
Who cannot take part
- Acute significant disease or illness within 7 days before the start of the trial
- History or regular use of tobacco or other nicotine-containing products within 6 months before the start of the trial
- Treatment with an investigational drug within 90 days or 5 half-lives (whichever is longer) or exposure to more than 3 investigational drugs within 12 months of first study drug administration
- Use of prescription medication (excluding female hormonal contraception or hormone replacement therapy)within 30 days or 5 half
- lives (whichever is longer) prior to first study drug administration, or use of over-the-counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations; Paracetamol use ≤2g per day is permitted) during the 14 days or 5 half-lives of the drug (whichever is longer) before first study drug administration
- Donation or loss of 450 mL or more of blood or plasma within 16 weeks prior to first trial medication administration or intention to donate blood in the 16 weeks after completing the trial
- Significant current or recurrent disease
- Positive test for alcohol, drugs of abuse, hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab)
- An estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2
- History of sensitivity/allergy to the study medications or components thereof (mannitol, colloidal anhydrous silica, glycerol dibehenate or magnesium-stearate)
- Clinically significant deviations in blood tests
- Pregnant or breastfeeding women
- An inability to follow a standardised diet and meal schedule or inability to fast, as required during the trial
- Participants deemed to have difficult veins for cannulation/blood draws
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomised, open-label study evaluating the pharmacokinetics, safety, and tolerability of a new once daily dose of 900mg of TETA 4HCL by comparing it against the current marketed Cuprior® formulation (450mg trientine base, twice daily) in healthy male and female participants.
The 2 groups in the trial
- Once Daily Dose Formulation (Treatment A)Treatment being tested
1 x 900mg TETA 4HCl, new once daily formulation (3x300mg trientine base tablets as a single AM dose)
Treatment: 900mg TETA 4HCl Once Daily Formulation
- Cuprior® comparator (Treatment B)Existing treatment, for comparison
2 x 450mg TETA 4HCl, Marketed Cuprior® formulation (6 x150mg trientine base tablets in two equally divided doses (450mg doses 8 hours apart)
Treatment: 900mg TETA 4HCl Cuprior®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I, Single Centre, Randomised, Interventional, Open-Label, Cross-Over Study to Evaluate the Pharmacokinetics (PK) and the Safety and Tolerability of a Total Daily Dose of 900mg of TETA 4HCL, Comparing a New Once Daily TETA 4HCL Formulation (300mg) (3x300mg Trientine Base Tablets, OD) With the Current Marketed Cuprior® Formulation (150mg) (3x150mg Trientine Base Tablets, BD) in Adult Healthy Male and Female Participants
- Record updated
- 26 August 2026